Cargando…
Matrix Metalloproteinase-9 (MMP-9) Gene Polymorphism in Stroke Patients
Matrix metalloproteinases (MMPs), endopeptidases degrading extracellular matrix, play an important role in the pathogenesis of atherosclerosis and vascular disease. The aim of this study was to evaluate the association between the C(-1562)T functional polymorphism in the MMP-9 gene and risk of strok...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643105/ https://www.ncbi.nlm.nih.gov/pubmed/26330106 http://dx.doi.org/10.1007/s12017-015-8367-5 |
_version_ | 1782400469552857088 |
---|---|
author | Buraczynska, Kinga Kurzepa, Jacek Ksiazek, Andrzej Buraczynska, Monika Rejdak, Konrad |
author_facet | Buraczynska, Kinga Kurzepa, Jacek Ksiazek, Andrzej Buraczynska, Monika Rejdak, Konrad |
author_sort | Buraczynska, Kinga |
collection | PubMed |
description | Matrix metalloproteinases (MMPs), endopeptidases degrading extracellular matrix, play an important role in the pathogenesis of atherosclerosis and vascular disease. The aim of this study was to evaluate the association between the C(-1562)T functional polymorphism in the MMP-9 gene and risk of stroke. We examined 322 patients with stroke and 410 controls. In the patient group, 52 % had type 2 diabetes. All subjects were genotyped for the C(-1562)T polymorphism by polymerase chain reaction and restriction analysis. A significant increase in T allele and CT + TT genotype frequencies was observed in patients compared with controls (OR 1.73, 95 % CI 1.34–2.23 and 1.89, 95 % CI 1.39–2.56, respectively). The T allele carriers were younger at the onset of stroke (63.5 ± 11.7 years) than patients with CC genotype (71 ± 14.1 years) (p = 0.0002). The comparison between patients with T2DM and without it showed that the T allele and CT + TT genotype were more frequent in T2DM patients (OR 1.48, 95 % CI 1.03–2.12 for T allele and 1.44, 95 % CI 1.93–2.24 for CT + TT genotype). In conclusion, our findings suggest that MMP-9 C(-1562)T polymorphism is significantly associated with risk of stroke in patients with and without T2DM. |
format | Online Article Text |
id | pubmed-4643105 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-46431052015-11-18 Matrix Metalloproteinase-9 (MMP-9) Gene Polymorphism in Stroke Patients Buraczynska, Kinga Kurzepa, Jacek Ksiazek, Andrzej Buraczynska, Monika Rejdak, Konrad Neuromolecular Med Original Paper Matrix metalloproteinases (MMPs), endopeptidases degrading extracellular matrix, play an important role in the pathogenesis of atherosclerosis and vascular disease. The aim of this study was to evaluate the association between the C(-1562)T functional polymorphism in the MMP-9 gene and risk of stroke. We examined 322 patients with stroke and 410 controls. In the patient group, 52 % had type 2 diabetes. All subjects were genotyped for the C(-1562)T polymorphism by polymerase chain reaction and restriction analysis. A significant increase in T allele and CT + TT genotype frequencies was observed in patients compared with controls (OR 1.73, 95 % CI 1.34–2.23 and 1.89, 95 % CI 1.39–2.56, respectively). The T allele carriers were younger at the onset of stroke (63.5 ± 11.7 years) than patients with CC genotype (71 ± 14.1 years) (p = 0.0002). The comparison between patients with T2DM and without it showed that the T allele and CT + TT genotype were more frequent in T2DM patients (OR 1.48, 95 % CI 1.03–2.12 for T allele and 1.44, 95 % CI 1.93–2.24 for CT + TT genotype). In conclusion, our findings suggest that MMP-9 C(-1562)T polymorphism is significantly associated with risk of stroke in patients with and without T2DM. Springer US 2015-09-02 2015 /pmc/articles/PMC4643105/ /pubmed/26330106 http://dx.doi.org/10.1007/s12017-015-8367-5 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Paper Buraczynska, Kinga Kurzepa, Jacek Ksiazek, Andrzej Buraczynska, Monika Rejdak, Konrad Matrix Metalloproteinase-9 (MMP-9) Gene Polymorphism in Stroke Patients |
title | Matrix Metalloproteinase-9 (MMP-9) Gene Polymorphism in Stroke Patients |
title_full | Matrix Metalloproteinase-9 (MMP-9) Gene Polymorphism in Stroke Patients |
title_fullStr | Matrix Metalloproteinase-9 (MMP-9) Gene Polymorphism in Stroke Patients |
title_full_unstemmed | Matrix Metalloproteinase-9 (MMP-9) Gene Polymorphism in Stroke Patients |
title_short | Matrix Metalloproteinase-9 (MMP-9) Gene Polymorphism in Stroke Patients |
title_sort | matrix metalloproteinase-9 (mmp-9) gene polymorphism in stroke patients |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643105/ https://www.ncbi.nlm.nih.gov/pubmed/26330106 http://dx.doi.org/10.1007/s12017-015-8367-5 |
work_keys_str_mv | AT buraczynskakinga matrixmetalloproteinase9mmp9genepolymorphisminstrokepatients AT kurzepajacek matrixmetalloproteinase9mmp9genepolymorphisminstrokepatients AT ksiazekandrzej matrixmetalloproteinase9mmp9genepolymorphisminstrokepatients AT buraczynskamonika matrixmetalloproteinase9mmp9genepolymorphisminstrokepatients AT rejdakkonrad matrixmetalloproteinase9mmp9genepolymorphisminstrokepatients |